5IU Stock Chart & Stats
€0.05
€0.01(5.26%)
At close: 4:00 PM EST
€0.05
€0.01(5.26%)
Day’s Range― - ―
52-Week Range€0.04 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)333.00
Market Cap
€21.56M
Enterprise Value€118.51
Total Cash (Recent Filing)€114.83M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding320,491,640
10 Day Avg. Volume1,000
30 Day Avg. Volume333
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtA debt-free balance sheet limits interest obligations and refinancing risk, giving Isofol greater flexibility to direct available capital toward oncology development and regulatory activities.
Oncology Drug CandidateThe candidate targets an established chemotherapy backbone and important cancer indications such as colorectal cancer, creating a potentially scalable clinical and partnering opportunity if efficacy and approval are achieved.
Positive Equity BasePositive equity and a substantial asset base provide some financial capacity for continued operations, reducing immediate balance-sheet distress risk even though ongoing development losses may gradually consume this capital.
Bears Say
No Meaningful RevenueThe absence of recurring product revenue confirms that Isofol remains pre-commercial, leaving future value dependent on clinical success, regulatory approval and eventual commercialization or partnering.
Persistent Cash BurnMaterial operating cash consumption means Isofol cannot currently fund its activities through operations, increasing reliance on cash reserves or external financing to sustain clinical and corporate development.
Ongoing LossesDeep operating and net losses indicate that the business has not yet demonstrated economic sustainability; continued losses can weaken the capital base and increase funding needs before any product launch.
Isofol Medical AB News
5IU FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was €0.04 and its highest was €0.09 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is €21.56M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Nov 12, 2026 which is in 41 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Aug 25, 2026. The company reported -€0.004 earnings per share for the quarter.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in DE:5IU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―